3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
18
Lung Neoplasms
8
Small Cell Lung Carcinoma
6
Neoplasms
4
Neoplasm Metastasis
4
Carcinoma, Hepatocellular
4
Carcinoma
4
Urinary Bladder Neoplasms
3
Pancreatic Neoplasms
3
Cholangiocarcinoma
3
Triple Negative Breast Neoplasms
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Liver Neoplasms
2
Gallbladder Neoplasms
2
Endometrial Neoplasms
2
Bile Duct Neoplasms
2
Vaccinia
1
Squamous Cell Carcinoma of Head and Neck
1
Resectable Intrahepatic Cholangiocarcinoma
1
Renal Pelvis and Ureter Urothelial Carcinoma
1
Pathologic Complete Response
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Non-Small Cell Lung Cancer Metastatic
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms, Glandular and Epithelial
1
Mouth Neoplasms
1
Liver Diseases
1
Laryngeal Neoplasms
1
Interventions
durvalumab
1
cemiplimab
1
atezolizumab
1
Sorafenib
1
Pemetrexed
1
Nivolumab
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Docetaxel
1
Cisplatin
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Vaccinia
×
durvalumab
×
30 days
×
Clear all
NCT06463665
2026-06-04
VIRO-25
Genelux Corporation
Phase 2
Recruiting
142 enrolled